ANI Pharmaceuticals appointed Henry Gosebruch to its Board of Directors effective August 19, 2026, with an initial restricted stock award valued at $525,000. Concurrently, Muthusamy "Samy" Shanmugam resigned as a director but will remain in his executive roles as Head of Research and Development and Chief Operating Officer of New Jersey Operations. The company operates in the biopharmaceutical industry, developing and commercializing therapeutics for rare diseases, generics, and branded products.

ANI Pharmaceuticals reported second quarter 2026 financial results with total net revenues of $266.0 million, a 25.9% increase year-over-year. Rare Disease segment revenues rose 30.7% to $135.8 million, driven by a 43.5% surge in Cortrophin Gel sales to $117.1 million and the operational launch of its gout expansion sales force. Generics revenues grew 9.7% to $99.1 million. The company reported GAAP net income of $24.7 million, or $1.05 per diluted share, compared to $8.1 million in the prior year period. Adjusted non-GAAP EBITDA increased 32.4% to $71.6 million. Management reaffirmed full-year 2026 guidance for total net revenue of $1,080-$1,140 million and adjusted non-GAAP EBITDA of $285-$300 million, while modestly lowering Cortrophin Gel guidance to $520-$540 million. The board authorized a share repurchase program for up to $100.0 million through May 2029. ANI Pharmaceuticals is a diversified biopharmaceutical company focused on developing and commercializing therapeutics in rare diseases, generics, and branded products.